The Presence of a BRCA Mutation in Patients with Breast Cancer
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Clinical Pearls
While a BRCA mutation used to be considered a negative prognostic factor in patients with breast cancer, it can now be considered a good thing, Daugherty says. Patients with the BRCA mutation are more amenable to platinum therapy and are eligible for PARP trials. It remains important for nurses and doctors to inform patients about new knowledge concerning BRCA.
- While the presence of a BRCA mutation used to be considered negative, it can now be considered positive, Daugherty says
- Patients with BRCA mutations are more amenable to platinum therapy and are eligible for PARP trials
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
